Heghine Khachatryan on VWD: A Landmark in the History of Hematology
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, sreposted from Haematologica Journal on LinkedIn:
”A Landmark in the History of Hematology
One hundred years ago, the Finnish physician Erik Adolf von Willebrand published his seminal description of hereditary pseudohemophilia, a disorder that would later bear his name as von Willebrand disease.
This groundbreaking work was the first to clearly demonstrate that:
• inherited bleeding disorders may affect both sexes,
• the clinical phenotype can differ fundamentally from classical hemophilia, and
• family-based observation and pedigree analysis are critical to understanding disorders of hemostasis.
-The original genealogical diagram, shown here, represents more than a historical artifact—it laid the scientific foundation for modern concepts of primary hemostasis, platelet–vessel wall interaction, and the role of von Willebrand factor in coagulation.
-A century later, von Willebrand’s observations continue to inform contemporary diagnostics, molecular genetics, and individualized therapeutic strategies in bleeding disorders.
This milestone reminds us that careful clinical observation remains the cornerstone of scientific progress, even in the era of advanced genomics and precision medicine.”
Quoting Haematologica Journal‘s post:
”Landmark paper in Hematology: One hundred years ago the Finnish physician Erik Adolf von Willebrand published his landmark paper on hereditary pseudohemophilia in Documents of the Finnish Society of Medicine: he had discovered the disease that nowadays we universally known by his name.”
Read the full article here.
Article: The landmark contribution by Erik von Willebrand
Authors: Riitta Lassila, Erik Berntorp
Stay updated on all scientific advances with Hemostasis Today.
-
May 30, 2026, 08:59Li-Chia Chen: Advancing Patient Care Through Pharmacist Innovation at KUTRRH
-
May 30, 2026, 08:58Ben Creagh-Brown: How Should HI-PEITHO Influence the Management of Intermediate-Risk Pulmonary Embolism?
-
May 30, 2026, 08:56Reidiel Suárez Borges: Understanding the INR in Anticoagulation Management
-
May 29, 2026, 17:23Rita Schwab: Current Clinical Management of Trauma without the Use of Allogenic Blood Products
-
May 29, 2026, 17:22Brian Schiro: Excited to Provide Guideline Based Care at the Aortic Center
-
May 29, 2026, 17:20Martin Widschwendter: How Molecular Detection Tests Could Transform Endometrial Cancer Care
-
May 29, 2026, 17:18Nina Lansbury: Supporting a Period Friendly World With Menstrual Health Research and Education
-
May 29, 2026, 17:16Ipsita Chatterjee: Red is Not Shame, Red is Power, Red is a Woman
-
May 29, 2026, 16:49Abdulrahman Nasiri: The Evolving Role of Romiplostim in SAA